Pivotal trial of CLN-081 in NSCLC patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Apr 2024 According to Cullinan Therapeutics media release, Cullinan Oncology has changed its name to Cullinan Therapeutics.
11 May 2023 According to an Cullinan Oncology media release, the company will continue the enrollment in this pivotal study at the 100mg BID dose only.
11 May 2023 According to an Cullinan Oncology media release, enrollment in the 150mg BID cohort of this study was recently discontinued based upon recommendation of the safety review committee.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com